ProfileGDS5678 / 1424817_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 11.847982
GSM967853U87-EV human glioblastoma xenograft - Control 21.836282
GSM967854U87-EV human glioblastoma xenograft - Control 31.837372
GSM967855U87-EV human glioblastoma xenograft - Control 41.780372
GSM967856U87-EV human glioblastoma xenograft - Control 51.821052
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 11.851032
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.857672
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.813982
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.79782
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 11.82842
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.830542
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.821472
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.828512
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 51.835052